drugset / Trial / NCT00990691

Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome

NCT00990691 ↗

Phase 2 Completed 36 enrolled Assistance Publique Hopitaux De Marseille
RandomizedParallel-groupDouble-blindTreatment

Summary

Rett syndrome is a neurodevelopmental disorder characterized by cognitive impairment, communication dysfunction, stereotypic movement disorder, and growth failure. Rett syndrome is caused by mutations in the Methyl CpG-Binding Protein-2 (MECP2) gene and has no treatment. A mouse experimental model of Rett syndrome created by genetic invalidation of the MECP2 gene is available. It had been then observed that adult MECP2-deficient mice show respiratory alterations and found that endogenous noradrenaline helps to maintain a normal respiratory rhythm. Desipramine, a selective inhibitor of norepinephrine reuptake, seems to be efficient to reduce the respiratory alteration occuring in MECP2-deficient mice (Insem patent 2005, Villard and Roux 2006). The aim of the study is to evaluate these obtained results in MECP2-deficient mice on patients with Rett syndrome.

Timeline

Start
2009-02-17
Primary completion
2014-08-11
Completion
2017-08-21

Outcome

Missed primary endpoint

paper We did not find any significant difference in these changes between the groups (P = 0.781). PMID 29468173 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Desipramine Small molecule 25 mg —
Subject Desipramine Small molecule 50 mg —
Subject Desipramine Small molecule 75 mg —
Subject Desipramine Small molecule 100 mg —
Subject Desipramine Small molecule 150 mg —

Indications